HUMAN leukocyte antigen (HLA)-DM is an unconventional major histocompatibility complex
(MHC) class II heterodimer that is important for B-cell-mediated antigen processing and …

Phosphodiesterase 4 (PDE4) is a key enzyme in the degradation of cyclic adenosine
monophosphate and is centrally involved in the cytokine production of inflammatory cells, …

Objective Bisphosphonates inhibit osteoclast activity, which is central to the development of
bone damage in rheumatoid arthritis (RA). The aim of this study was to assess whether …

OBJECTIVE: The OMERACT Drug Safety Working Group focuses on standardization of
assessment and reporting of adverse events in clinical trials and longitudinal and observational …

… This article was prepared by Victor Sloan in his personal capacity. The views expressed
are his own and do not reflect the views of the Peace Corps or the US Government. …

Objective: To determine the efficacy and safety of lumiracoxib for knee osteoarthritis (OA).
Methods: This was a 13-week, multicentre, randomized, double-blind, double-dummy, placebo-…

Several noncardiac drugs have been linked to cardiac safety concerns, highlighting the
importance of post‐marketing surveillance and continued evaluation of the benefit‐risk of long‐…

BACKGROUND:: Lumiracoxib is a cyclooxygenase-2-selectiveinhibitor developed for the
treatment of osteoarthritis (OA), rheumatoid arthritis, and acute pain. OBJECTIVES:: This study …

HLA-DM catalyzes the release of invariant chain fragments from newly synthesized major
histocompatibility complex (MHC) class II molecules, stabilizes empty class II molecules, and …

Objective. To assess the prevalence of chronic opioid use in patients with ankylosing spondylitis
(AS), and to compare the characteristics of patients with and without chronic opioid use. …